A PHASE 3 PROSPECTIVE, UNCONTROLLED, MULTICENTER STUDY EVALUATING PHARMACOKINETICS, EFFICACY, SAFETY, AND IMMUNOGENICITY OF BAX 855 (PEGYLATEDFULL-LENGTH RECOMBINANT FVIII) IN PREVIOUSLY TREATED PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A